PH-762

Phase 1Small molecule

PPhio Pharmaceuticals Inc.

PH-762 is one of 14 small molecule programs targeting Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CarcinomaActive, not recruiting

CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Carcinoma

#DrugCompanyPhaseTrials

Afinitor

Novartis

Phase 3

1 2

Fludara

Sanofi

Phase 2

1 3

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 4

Klisyri

AAlmirall, S.A.

Phase 2

1 5

TQB3454

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Administration of AVP

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 8

PH-762

PPhio Pharmaceuticals Inc.

Phase 1

1 9

SZ011 CAR-NK

SShantou University Medical College

Phase 1

1 10

Ga-NOTA-T4

RRenJi Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Carcinoma1 trial

Intratumoral PH-762 for Cutaneous Carcinoma

Active, not recruiting·PPhio Pharmaceuticals Inc.·Phase 1·NCT06014086·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PH-762. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PH-762 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PH-762. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phio Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPhio Pharmaceuticals Inc.

PH-762

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Carcinoma1 trial

References

Drug Info

Quick Facts

Related News